In cancer patients, tumor infiltrating phenotypically defined CD103+CD8+ Trm cells were a better predictor of survival than CD8+ T cells, and the density of CD8+ T cells with a Trm transcriptional signature correlated with survival and immunotherapy response(reviewed in10). The gene discussed is CD8A; the disease is cancer.